Postoperative adjuvant therapy for resectable early non-small cell lung cancer A protocol for a systematic review and meta-analysis

被引:5
|
作者
Chai, Tianci [1 ,2 ]
Zhang, Peipei [1 ,2 ]
Lin, Yuhan [3 ]
Zhang, Zhenyang [1 ]
Lin, Wenwei [1 ]
Kang, Mingqiang [1 ]
Lin, Jiangbo [1 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Thorac Surg, 29 New Power Rd, Fuzhou 350004, Fujian, Peoples R China
[2] Fujian Med Univ, Grad Sch, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Sch Stomatol, Fuzhou, Fujian, Peoples R China
关键词
chemotherapy; immunotherapy; molecular targeted therapy; non-small cell lung cancer; radiotherapy; STAGE-II;
D O I
10.1097/MD.0000000000016468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lung cancer is one of the most common malignant tumors, and non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer diagnosed. For patients with resectable early stage non-small cell lung cancer, routine postoperative adjuvant therapy can significantly prolong overall patient survival and reduce the risk of cancer recurrence. With the emergence and maturity of molecular targeted therapy and immunotherapy, the postoperative chemotherapy strategy of lung cancer patients has changed a lot. To evaluate the efficacy of postoperative adjuvant therapy (platinum-based chemotherapy, platinum-based chemotherapy plus molecular targeted therapy, platinum-based chemotherapy plus anti-angiogenic agents, or platinum-based chemotherapy plus immunotherapy) with or without radiotherapy for patients with NSCLC, we will conduct a systematic review and meta-analysis of the published or unpublished relevant randomized controlled trials. Methods: We will search PubMed (Medline), Embase, Google Scholar, Cancerlit, and the Cochrane Central Register of Controlled Trials for related studies published without language restrictions before June 20, 2019. Two review authors will search and assess relevant studies independently. Randomized controlled trials (RCTs) and quasi-RCTs studies will be included. We will perform subgroup analysis in different methods of postoperative adjuvant therapy for patients with resectable early NSCLC. Because this study will be based on published or unpublished records and studies, there is no need for ethics approval. Results: The results of this study will be published in a peer-reviewed journal. Conclusion: This study will comprehensively compare the efficacy of platinum-based chemotherapy with that of molecular targeted therapy and immunotherapy for patients after surgery with resectable early NSCLC. Since large-sample randomized trials meeting the inclusion criteria of this study may be insufficient, we will consider incorporating some high-quality small-sample-related trials, which may lead to high heterogeneity and affect the reliability of the results.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Platinum versus immunotherapy for early resectable non-small cell lung cancer A protocol for systematic review and meta analysis
    Tong, Zhangwei
    Luo, Fei
    Yang, Xiaojie
    Kang, Mingqiang
    Lin, Jiangbo
    MEDICINE, 2020, 99 (43)
  • [2] Postoperative adjuvant therapy for resectable esophageal cancer A protocol of a systematic review and meta-analysis
    Chai, Tianci
    Shen, Zhimin
    Zhang, Peipei
    Lin, Yuhan
    Chen, Sui
    Zhang, Zhenyang
    Lin, Wenwei
    Kang, Mingqiang
    Lin, Jiangbo
    MEDICINE, 2019, 98 (20)
  • [3] Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis
    Wu, Yajing
    Verma, Vivek
    Gay, Carl M.
    Chen, Yujia
    Liang, Fei
    Lin, Qiang
    Wang, Jianing
    Zhang, Wei
    Hui, Zhouguang
    Zhao, Min
    Wang, Jun
    Chang, Joe Y.
    CANCER, 2023, 129 (13) : 1969 - 1985
  • [4] Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
    Zhang, Qiong
    Duan, Jia
    Zhang, Yuanmei
    Yang, Lei
    Li, Duo
    SYSTEMATIC REVIEWS, 2025, 14 (01)
  • [5] Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
    Cao, Christopher
    Le, Anthony
    Bott, Matthew
    Yang, Chi-Fu Jeffrey
    Gossot, Dominique
    Melfi, Franca
    Tian, David H.
    Guo, Allen
    CURRENT ONCOLOGY, 2021, 28 (06) : 4686 - 4701
  • [6] Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Lei, Tianyu
    Li, Jing
    Zhong, Hao
    Zhang, Huibo
    Jin, Yan
    Wu, Jie
    Li, Lan
    Xu, Bin
    Song, Qibin
    Hu, Qinyong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis
    Mei, T.
    Zhou, Q.
    Gong, Y.
    CLINICAL ONCOLOGY, 2024, 36 (02) : 107 - 118
  • [8] The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer: An updated systematic review and meta-analysis
    Wang, Zexu
    Yang, Baixia
    Zhan, Ping
    Wang, Li
    Wan, Bing
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (07) : 1910 - +
  • [9] Systematic review and meta-analysis of Chinese herbal medicine as adjuvant treatment in advanced non-small cell lung cancer patients
    Wang, Li-Chi
    Chang, Yong-Yuan
    Lee, I-Chen
    Kuo, Heng-Chun
    Tsai, Ming-Yen
    COMPLEMENTARY THERAPIES IN MEDICINE, 2020, 52
  • [10] Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer: A protocol for systematic review and meta-analysis
    Zhu, Qunying
    Chen, Guini
    Liu, Yunzhong
    Zhou, Yu
    MEDICINE, 2023, 102 (09) : E33166